Hikma Pharmaceuticals Regulatory News (HIK)

London, 17 July 2023 - Hikma Pharmaceuticals PLC (Hikma, Group), will announce its interim financial results for the six months ended 30 June 2023 on Thursday 3 August 2023.

A recording of the presentation will be available on the Group's website at www.hikma.com from 7:00am BST. Hikma will also hold a live Q&A conference call for analysts at 9:30am BST, and a recording will be made available on the Company's website.

To join via conference call please dial:

United Kingdom (local): +44 20 4587 0498United Kingdom (toll-free): +44 800 358 1035 Global Dial-In NumbersAccess Code: 317158

For further information please contact Tiina Lugmayer - tlugmayer@hikma.com.

- ENDS -

Enquiries

Hikma Pharmaceuticals PLC

Teneo

Charles Armitstead +44 (0)7703 330 269

About Hikma

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P and BBB-/positive Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,800 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com